{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:49:42Z","timestamp":1793022582039,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.maturitas.2026.109116","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:09:43Z","timestamp":1789027783000},"page":"109116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy"],"prefix":"10.1016","volume":"214","author":[{"given":"Diogo Pinto da Costa","family":"Viana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Luckow","family":"Invitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Schor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2026.109116_bb0005","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.maturitas.2026.109116_bb0010","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/oby.23612","article-title":"Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program","volume":"31","author":"Le Roux","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.maturitas.2026.109116_bb0015","article-title":"Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Tian","year":"2025","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.maturitas.2026.109116_bb0020","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1007\/s00125-024-06144-1","article-title":"Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials","volume":"67","author":"Karagiannis","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.maturitas.2026.109116_bb0025","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.2147\/DDDT.S506957","article-title":"A comprehensive review on the pharmacokinetics and drug\u2013drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist","volume":"19","author":"Min","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.maturitas.2026.109116_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12103388","article-title":"Understanding progestins: from basics to clinical applicability","volume":"12","author":"Garc\u00eda-S\u00e1enz","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.maturitas.2026.109116_bb0035","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1089\/jwh.2010.2199","article-title":"Tailoring combination oral contraceptives to the individual woman","volume":"20","author":"Archer","year":"2011","journal-title":"J. Women's Health (Larchmt)"},{"key":"10.1016\/j.maturitas.2026.109116_bb0040","article-title":"Menopause, obesity and incretin therapy: new horizons in women\u2019s metabolic health","volume":"69","author":"Ushanova","year":"2025","journal-title":"Obstet Gynecol Reprod (Mosc)"},{"key":"10.1016\/j.maturitas.2026.109116_bb0045","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2217\/WHE.13.41","article-title":"Obesity and hormonal contraceptive efficacy","volume":"9","author":"Robinson","year":"2013","journal-title":"Womens Health (Lond)"},{"key":"10.1016\/j.maturitas.2026.109116_bb0050","article-title":"Obesity and gynaecological and obstetric conditions: umbrella review of the literature","volume":"359","author":"Kalliala","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2026.109116_bb0055","article-title":"Obesity and risk of female reproductive conditions: a Mendelian randomisation study","volume":"19","author":"Venkatesh","year":"2022","journal-title":"PLoS Med."},{"key":"10.1016\/j.maturitas.2026.109116_bb0060","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.japh.2023.10.037","article-title":"The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception","volume":"64","author":"Skelley","year":"2024","journal-title":"J. Am. Pharm. Assoc."},{"issue":"S1","key":"10.1016\/j.maturitas.2026.109116_bb0065","article-title":"Glucagon-like peptide-1 receptor agonists and cardiometabolic risk factors in polycystic ovary syndrome: role of race\/ethnicity","volume":"38","author":"Pruett","year":"2023","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.maturitas.2026.109116_bb0070","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/GME.0000000000002310","article-title":"Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use","volume":"31","author":"Hurtado","year":"2024","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2026.109116_bb0075","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/S3050-5038(25)00145-1","article-title":"The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study","volume":"2","author":"Castaneda","year":"2026","journal-title":"Lancet Obstet. Gynecol. Womens Health"},{"key":"10.1016\/j.maturitas.2026.109116_bb0080","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/phar.70007","article-title":"GLP-1RA-induced delays in gastrointestinal motility: predicted effects on coadministered drug absorption by PBPK analysis","volume":"45","author":"Hooper","year":"2025","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.maturitas.2026.109116_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2026.109116_bb0090","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2026.109116_bb0095","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.maturitas.2026.109116_bb0100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2026.109116_bb0105","series-title":"MOUNJARO (Tirzepatide) Injection, for Subcutaneous Use: US Prescribing Information","author":"Eli Lilly and Company","year":"2022"},{"key":"10.1016\/j.maturitas.2026.109116_bb0110","series-title":"FSRH Statement: Glucagon-like Peptide-1 (GLP-1) Agonists and Oral Contraception","author":"Faculty of Sexual and Reproductive Healthcare","year":"2025"},{"key":"10.1016\/j.maturitas.2026.109116_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2026.109116_bb0120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/20533691251343069","article-title":"Use of incretin-based therapies in women using hormone replacement therapy (HRT)","volume":"31","author":"Mukherjee","year":"2025","journal-title":"Post Reprod. Health"},{"key":"10.1016\/j.maturitas.2026.109116_bb0125","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.fertnstert.2024.04.036","article-title":"The impact of obesity on reproductive health and metabolism in reproductive-age females","volume":"122","author":"Schon","year":"2024","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.maturitas.2026.109116_bb0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13058-016-0791-4","article-title":"Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients","volume":"19","author":"Mullooly","year":"2017","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.maturitas.2026.109116_bb0135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1530\/JOE-20-0446","article-title":"Obesity is associated with heavy menstruation that may be due to delayed endometrial repair","volume":"249","author":"Reavey","year":"2021","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.maturitas.2026.109116_bb0140","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2013776118","article-title":"Macrophages inhibit and enhance endometriosis depending on their origin","volume":"118","author":"Hogg","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.maturitas.2026.109116_bb0145","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/s43587-024-00767-0","article-title":"Exploring the effects of estrogen deficiency and aging on organismal homeostasis during menopause","volume":"4","author":"Camon","year":"2024","journal-title":"Nat. Aging"},{"key":"10.1016\/j.maturitas.2026.109116_bb0150","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2026.109116_bb0155","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society","volume":"29","year":"2022","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2026.109116_bb0160","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s11154-024-09882-0","article-title":"Diagnostic and therapeutic use of oral micronized progesterone in endocrinology","volume":"25","author":"Memi","year":"2024","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.maturitas.2026.109116_bb0165","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/er.2012-1008","article-title":"Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects","volume":"34","author":"Stanczyk","year":"2013","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.maturitas.2026.109116_bb0170","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2217\/17455057.3.4.409","article-title":"Combination of drospirenone and estradiol: a new hormone therapy in postmenopausal women","volume":"3","author":"Huber","year":"2007","journal-title":"Womens Health (Lond)"},{"key":"10.1016\/j.maturitas.2026.109116_bb0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.maturitas.2003.09.014","article-title":"Classification and pharmacology of progestins","volume":"46","author":"Schindler","year":"2003","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2026.109116_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ph17091248","article-title":"Effects, doses, and applicability of gestrinone in estrogen-dependent conditions and post-menopausal women","volume":"17","author":"Renke","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.maturitas.2026.109116_bb0185","first-page":"44","article-title":"Treatment of large fibroids with high doses of gestrinone","volume":"30","author":"Coutinho","year":"1990","journal-title":"Gynecol. Obstet. Investig."},{"key":"10.1016\/j.maturitas.2026.109116_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17050638","article-title":"Safety profile of gestrinone: a systematic review","volume":"17","author":"Fagundes","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.maturitas.2026.109116_bb0195","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1080\/13697137.2020.1806816","article-title":"Uterine bleeding with hormone therapies in menopausal women: a systematic review","volume":"23","author":"Pickar","year":"2020","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2026.109116_bb0200","first-page":"13","article-title":"Abnormal bleeding during menopause hormone therapy: insights for clinical management","volume":"6","author":"De Medeiros","year":"2013","journal-title":"Clin. Med. Insights Womens Health"},{"key":"10.1016\/j.maturitas.2026.109116_bb0205","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40264-023-01392-3","article-title":"Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review","volume":"47","author":"Calvarysky","year":"2024","journal-title":"Drug Saf."},{"key":"10.1016\/j.maturitas.2026.109116_bb0210","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3109\/13697137.2014.991302","article-title":"The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review","volume":"18","author":"Depypere","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2026.109116_bb0215","doi-asserted-by":"crossref","first-page":"7","DOI":"10.24926\/iip.v10i3.2002","article-title":"Benefits of levonorgestrel intrauterine device use vs oral or transdermal progesterone for postmenopausal women using estrogen containing hormone therapy","volume":"10","author":"Clark","year":"2019","journal-title":"Innov Pharm"},{"key":"10.1016\/j.maturitas.2026.109116_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27072988","article-title":"Disproportionality analysis of tirzepatide vs semaglutide and liraglutide: system organ class-level post-marketing reporting patterns in EudraVigilance","volume":"27","author":"Marin","year":"2026","journal-title":"Int. J. Mol. Sci."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226002938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226002938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:21:24Z","timestamp":1793020884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512226002938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":44,"alternative-id":["S0378512226002938"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.109116","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.109116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109116"}}